Posted inCardiology news
LOX‑1 Blockade After MI Reduced sLOX‑1 and IL‑6 but Not Coronary Noncalcified Plaque: Lessons from GOLDILOX‑TIMI 69
In a randomized phase 2 trial, the anti‑LOX‑1 antibody MEDI6570 lowered circulating sLOX‑1 and IL‑6 but failed to reduce noncalcified coronary plaque volume versus placebo in post‑MI patients with residual inflammation.